-+ 0.00%
-+ 0.00%
-+ 0.00%

Innocan Pharma FY26 Q2 operating loss swings to US$0.51 million; revenue falls 25.06% to US$5.25 million

PUBT·08/31/2026 20:01:33
Listen to the news
Innocan Pharma FY26 Q2 operating loss swings to US$0.51 million; revenue falls 25.06% to US$5.25 million
  • Innocan posted Q2 fiscal 2026 revenue of US$5.25 million, down 25.06% year over year.
  • Operating results swung to a loss of US$508,000 from operating profit, as policy shifts on customs duties and tariffs hurt sales.
  • Gross margin widened 2.4 percentage points to 90.8%.
  • VALITIC maintained a leading Amazon category ranking, retaining the “Best Seller” badge and Amazon’s Choice recognition.
  • BI Sky is expanding beyond Amazon via major U.S. retail and distribution networks, increasing online-platform reach, and launching its DTC website.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innocan Pharma Ltd. published the original content used to generate this news brief via CNW (Ref. ID: 202608311601CANADANWCANADAPR_C5299) on August 31, 2026, and is solely responsible for the information contained therein.